The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Abstract
The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews," and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure--one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
System, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
Self-citationExtended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,044
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H. W., Scheld, W. M., Bartlett, J. G., Edwards, J., & the Infectious Diseases Society of America (2008) · Clinical Infectious Diseases · doi:10.1086/524891 · Cited by 1,642
Self-citationNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., & Bonomo, R. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01464-06 · Cited by 1,139
Cited by
Items 101–200 of 214
Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future
Rodvold, K. A., & McConeghy, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit614 · Cited by 358
A Dual-Mechanism Antibiotic Kills Gram-Negative Bacteria and Avoids Drug Resistance
Martin, J. K., Sheehan, J. P., Bratton, B. P., Moore, G. M., Mateus, A., Li, S. H.-J., Kim, H., Rabinowitz, J. D., Typas, A., Savitski, M. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.005 · Cited by 356
Nation, R. L., Li, J., Cars, O., Couet, W., Dudley, M. N., Kaye, K. S., Mouton, J. W., Paterson, D. L., Tam, V. H., Theuretzbacher, U., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70850-3 · Cited by 354
Antibiotic Discovery: Where Have We Come from, Where Do We Go?
Ribeiro da Cunha, B., Fonseca, L. P., & Calado, C. R. C. (2019) · Antibiotics · doi:10.3390/antibiotics8020045 · Cited by 353
Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action
Carlet, J., Jarlier, V., Harbarth, S., Voss, A., Goossens, H., Pittet, D., & Forum, T. P. O. T. 3. W. H.-A. I. (2012) · Antimicrobial Resistance and Infection Control · doi:10.1186/2047-2994-1-11 · Cited by 350
The rising problem of antimicrobial resistance in the intensive care unit
Brusselaers, N., Vogelaers, D., & Blot, S. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-47 · Cited by 350
Metal organic framework-based antibacterial agents and their underlying mechanisms
Han, D., Liu, X., & Wu, S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00460g · Cited by 349
Microbial Biofilms and Chronic Wounds
Omar, A., Wright, J., Schultz, G., Burrell, R., & Nadworny, P. (2017) · Microorganisms · doi:10.3390/microorganisms5010009 · Cited by 348
Nathwani, D., Raman, G., Sulham, K., Gavaghan, M., & Menon, V. (2014) · Antimicrobial Resistance and Infection Control · doi:10.1186/2047-2994-3-32 · Cited by 344
Genomic surveillance for antimicrobial resistance — a One Health perspective
Djordjevic, S. P., Jarocki, V. M., Seemann, T., Cummins, M. L., Watt, A. E., Drigo, B., Wyrsch, E. R., Reid, C. J., Donner, E., & Howden, B. P. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-023-00649-y · Cited by 342
Freire-Moran, L., Aronsson, B., Manz, C., Gyssens, I. C., So, A. D., Monnet, D. L., & Cars, O. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.02.003 · Cited by 335
Burckhardt, I., & Zimmermann, S. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00287-11 · Cited by 335
Hollmann, A., Martinez, M., Maturana, P., Semorile, L. C., & Maffia, P. C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00204 · Cited by 334
Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis
Harbut, M. B., Vilchèze, C., Luo, X., Hensler, M. E., Guo, H., Yang, B., Chatterjee, A. K., Nizet, V., Jacobs, W. R., Schultz, P. G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504022112 · Cited by 330
Dhingra, S., Rahman, N. A. A., Peile, E., Rahman, M., Sartelli, M., Hassali, M. A., Islam, T., Islam, S., & Haque, M. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.535668 · Cited by 329
Collignon, P. C., Conly, J. M., Andremont, A., McEwen, S. A., & Aidara-Kane, A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw475 · Cited by 328
Russo, T. A., Luke, N. R., Beanan, J. M., Olson, R., Sauberan, S. L., MacDonald, U., Schultz, L. W., Umland, T. C., & Campagnari, A. A. (2010) · Infection and Immunity · doi:10.1128/iai.00366-10 · Cited by 324
Karaiskos, I., & Giamarellou, H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.914172 · Cited by 324
de la Fuente-Núñez, C., Reffuveille, F., Mansour, S. C., Reckseidler-Zenteno, S. L., Hernández, D., Brackman, G., Coenye, T., & Hancock, R. E. W. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.01.002 · Cited by 323
Molecular mechanisms related to colistin resistance in Enterobacteriaceae
Aghapour, Z., Gholizadeh, P., Ganbarov, K., bialvaei, A. Z., Mahmood, S. S., Tanomand, A., Yousefi, M., Asgharzadeh, M., Yousefi, B., & Samadi Kafil, H. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s199844 · Cited by 320
Antibiotic Adjuvants: Diverse Strategies for Controlling Drug‐Resistant Pathogens
Gill, E. E., Franco, O. L., & Hancock, R. E. W. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12478 · Cited by 319
Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors
Cusumano, C. K., Pinkner, J. S., Han, Z., Greene, S. E., Ford, B. A., Crowley, J. R., Henderson, J. P., Janetka, J. W., & Hultgren, S. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003021 · Cited by 318
The Continuing Threat of Methicillin-Resistant Staphylococcus aureus
Gajdács, M. (2019) · Antibiotics · doi:10.3390/antibiotics8020052 · Cited by 318
The diversity of Klebsiella pneumoniae surface polysaccharides
Follador, R., Heinz, E., Wyres, K. L., Ellington, M. J., Kowarik, M., Holt, K. E., & Thomson, N. R. (2016) · Microbial Genomics · doi:10.1099/mgen.0.000073 · Cited by 317
Cerceo, E., Deitelzweig, S. B., Sherman, B. M., & Amin, A. N. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2015.0220 · Cited by 313
Biomimetic antimicrobial polymers: recent advances in molecular design
Ergene, C., Yasuhara, K., & Palermo, E. F. (2018) · Polymer Chemistry · doi:10.1039/c8py00012c · Cited by 312
The next generation of bacteriophage therapy
Lu, T. K., & Koeris, M. S. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.028 · Cited by 312
Emerging rules for effective antimicrobial coatings
Salwiczek, M., Qu, Y., Gardiner, J., Strugnell, R. A., Lithgow, T., McLean, K. M., & Thissen, H. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.09.008 · Cited by 312
The enhanced permeability retention effect: a new paradigm for drug targeting in infection
Azzopardi, E. A., Ferguson, E. L., & Thomas, D. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks379 · Cited by 312
Zavascki, A. P., Carvalhaes, C. G., Picão, R. C., & Gales, A. C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.108 · Cited by 312
A rapid antimicrobial susceptibility test based on single-cell morphological analysis
Choi, J., Yoo, J., Lee, M., Kim, E.-G., Lee, J. S., Lee, S., Joo, S., Song, S. H., Kim, E.-C., Lee, J. C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009650 · Cited by 311
Chimeric peptidomimetic antibiotics against Gram-negative bacteria
Luther, A., Urfer, M., Zahn, M., Müller, M., Wang, S.-Y., Mondal, M., Vitale, A., Hartmann, J.-B., Sharpe, T., Monte, F. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1665-6 · Cited by 311
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance
Wohlkonig, A., Chan, P. F., Fosberry, A. P., Homes, P., Huang, J., Kranz, M., Leydon, V. R., Miles, T. J., Pearson, N. D., Perera, R. L., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1892 · Cited by 310
Resistance in antimicrobial photodynamic inactivation of bacteria
Maisch, T. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c5pp00037h · Cited by 307
Nesme, J., & Simonet, P. (2015) · Environmental Microbiology · doi:10.1111/1462-2920.12631 · Cited by 303
Glycopeptide antibiotics: Back to the future
Butler, M. S., Hansford, K. A., Blaskovich, M. A. T., Halai, R., & Cooper, M. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.111 · Cited by 303
Antibacterial Liquid Metals: Biofilm Treatment via Magnetic Activation
Elbourne, A., Cheeseman, S., Atkin, P., Truong, N. P., Syed, N., Zavabeti, A., Mohiuddin, M., Esrafilzadeh, D., Cozzolino, D., McConville, C. F., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b07861 · Cited by 302
Emergence of Imipenem-Resistant Gram-Negative Bacilli in Intestinal Flora of Intensive Care Patients
Armand-Lefèvre, L., Angebault, C., Barbier, F., Hamelet, E., Defrance, G., Ruppé, E., Bronchard, R., Lepeule, R., Lucet, J.-C., El Mniai, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01823-12 · Cited by 300
Magiorakos, A. P., Burns, K., Rodríguez Baño, J., Borg, M., Daikos, G., Dumpis, U., Lucet, J. C., Moro, M. L., Tacconelli, E., Simonsen, G. S., et al. (2017) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-017-0259-z · Cited by 297
History of antimicrobial drug discovery: Major classes and health impact
Aminov, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.001 · Cited by 296
Acinetobacter baumannii Resistance: A Real Challenge for Clinicians
Vázquez-López, R., Solano-Gálvez, S. G., Juárez Vignon-Whaley, J. J., Abello Vaamonde, J. A., Padró Alonzo, L. A., Rivera Reséndiz, A., Muleiro Álvarez, M., Vega López, E. N., Franyuti-Kelly, G., Álvarez-Hernández, D. A., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9040205 · Cited by 296
Bui, V., Park, D., & Lee, Y.-C. (2017) · Polymers · doi:10.3390/polym9010021 · Cited by 295
Antibiotics and antiseptics for venous leg ulcers
O'Meara, S., Al-Kurdi, D., Ologun, Y., Ovington, L. G., Martyn-St James, M., & Richardson, R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003557.pub5 · Cited by 292
Resources for Genetic and Genomic Analysis of Emerging Pathogen Acinetobacter baumannii
Gallagher, L. A., Ramage, E., Weiss, E. J., Radey, M., Hayden, H. S., Held, K. G., Huse, H. K., Zurawski, D. V., Brittnacher, M. J., & Manoil, C. (2015) · Journal of Bacteriology · doi:10.1128/jb.00131-15 · Cited by 291
Methicillin resistance in Staphylococcus aureus requires glycosylated wall teichoic acids
Brown, S., Xia, G., Luhachack, L. G., Campbell, J., Meredith, T. C., Chen, C., Winstel, V., Gekeler, C., Irazoqui, J. E., Peschel, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209126109 · Cited by 290
The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00151 · Cited by 288
Multidrug-Resistant Gram-Negative Infections: What are the Treatment Options?
Giamarellou, H., & Poulakou, G. (2009) · Drugs · doi:10.2165/11315690-000000000-00000 · Cited by 288
Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., et al. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.05.011 · Cited by 287
Towards an integrated model of bacterial conjugation
Cabezón, E., Ripoll-Rozada, J., Peña, A., de la Cruz, F., & Arechaga, I. (2014) · FEMS Microbiology Reviews · doi:10.1111/1574-6976.12085 · Cited by 286
Streptococcus pneumoniae’s Virulence and Host Immunity: Aging, Diagnostics, and Prevention
Brooks, L. R. K., & Mias, G. I. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01366 · Cited by 286
Durand-Réville, T. F., Guler, S., Comita-Prevoir, J., Chen, B., Bifulco, N., Huynh, H., Lahiri, S., Shapiro, A. B., McLeod, S. M., Carter, N. M., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.104 · Cited by 285
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 285
An overview of antimicrobial peptides and the latest advances in their development
Sierra, J. M., Fusté, E., Rabanal, F., Vinuesa, T., & Viñas, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1315402 · Cited by 283
Structural determinants of antimicrobial activity in polymers which mimic host defense peptides
Palermo, E. F., & Kuroda, K. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-2687-z · Cited by 281
Recent Progress in Polymer Research to Tackle Infections and Antimicrobial Resistance
Konai, M. M., Bhattacharjee, B., Ghosh, S., & Haldar, J. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00458 · Cited by 281
Bender, J. K., Cattoir, V., Hegstad, K., Sadowy, E., Coque, T. M., Westh, H., Hammerum, A. M., Schaffer, K., Burns, K., Murchan, S., et al. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.10.002 · Cited by 281
Micek, S. T., Welch, E. C., Khan, J., Pervez, M., Doherty, J. A., Reichley, R. M., & Kollef, M. H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01365-09 · Cited by 278
Ramasamy, M., & Lee, J. (2016) · BioMed Research International · doi:10.1155/2016/1851242 · Cited by 278
Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?
Clancy, C. J., & Nguyen, M. H. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa524 · Cited by 274
Starkey, M., Lepine, F., Maura, D., Bandyopadhaya, A., Lesic, B., He, J., Kitao, T., Righi, V., Milot, S., Tzika, A., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004321 · Cited by 273
Antibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry
De Silva, D. D., Rapior, S., Sudarman, E., Stadler, M., Xu, J., Aisyah Alias, S., & Hyde, K. D. (2013) · Fungal Diversity · doi:10.1007/s13225-013-0265-2 · Cited by 271
The Concept of an Ideal Antibiotic: Implications for Drug Design
Gajdács, M. (2019) · Molecules · doi:10.3390/molecules24050892 · Cited by 271
How to Enter a Bacterium: Bacterial Porins and the Permeation of Antibiotics
Prajapati, J. D., Kleinekathöfer, U., & Winterhalter, M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01213 · Cited by 271
Raman, G., Avendano, E. E., Chan, J., Merchant, S., & Puzniak, L. (2018) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-018-0370-9 · Cited by 269
Marra, A. R., Camargo, L. F. A., Pignatari, A. C. C., Sukiennik, T., Behar, P. R. P., Medeiros, E. A. S., Ribeiro, J., Girão, E., Correa, L., Guerra, C., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00376-11 · Cited by 269
Puca, V., Marulli, R. Z., Grande, R., Vitale, I., Niro, A., Molinaro, G., Prezioso, S., Muraro, R., & Di Giovanni, P. (2021) · Antibiotics · doi:10.3390/antibiotics10101162 · Cited by 268
Principles of Judicious Antibiotic Prescribing for Upper Respiratory Tract Infections in Pediatrics
Hersh, A. L., Jackson, M. A., Hicks, L. A., the COMMITTEE ON INFECTIOUS DISEASES, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Maldonado, Y. A., Murray, D. L., et al. (2013) · Pediatrics · doi:10.1542/peds.2013-3260 · Cited by 266
Efficacy and safety of tigecycline: a systematic review and meta-analysis
Yahav, D., Lador, A., Paul, M., & Leibovici, L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr242 · Cited by 266
Amikacin: Uses, Resistance, and Prospects for Inhibition
Ramirez, M., & Tolmasky, M. (2017) · Molecules · doi:10.3390/molecules22122267 · Cited by 265
The global need for effective antibiotics: challenges and recent advances
Högberg, L. D., Heddini, A., & Cars, O. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.002 · Cited by 264
Ilangovan, A., Fletcher, M., Rampioni, G., Pustelny, C., Rumbaugh, K., Heeb, S., Cámara, M., Truman, A., Chhabra, S. R., Emsley, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003508 · Cited by 264
Commercial Essential Oils as Potential Antimicrobials to Treat Skin Diseases
Orchard, A., & van Vuuren, S. (2017) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2017/4517971 · Cited by 262
Hu, H., Wang, J., Li, J., Li, J., Ma, Y., Chen, D., & He, J. (2016) · Environmental Microbiology · doi:10.1111/1462-2920.13370 · Cited by 261
Colistin: new lessons on an old antibiotic
Yahav, D., Farbman, L., Leibovici, L., & Paul, M. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03734.x · Cited by 259
Ashiru-Oredope, D., Sharland, M., Charani, E., McNulty, C., Cooke, J., & on behalf of ARHAI Antimicrobial Stewardship Group (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks202 · Cited by 256
Behavior Change Strategies to Influence Antimicrobial Prescribing in Acute Care: A Systematic Review
Charani, E., Edwards, R., Sevdalis, N., Alexandrou, B., Sibley, E., Mullett, D., Franklin, B. D., & Holmes, A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir445 · Cited by 256
Industrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Plant and Animal Sensors of Conserved Microbial Signatures
Ronald, P. C., & Beutler, B. (2010) · Science · doi:10.1126/science.1189468 · Cited by 254
Chalcone derivatives and their antibacterial activities: Current development
Xu, M., Wu, P., Shen, F., Ji, J., & Rakesh, K. P. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103133 · Cited by 254
Synthesis, Self-Assembly, and Biomedical Applications of Antimicrobial Peptide–Polymer Conjugates
Sun, H., Hong, Y., Xi, Y., Zou, Y., Gao, J., & Du, J. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00208 · Cited by 253
Outpatient antibiotic prescribing in the United States: 2000 to 2010
Lee, G. C., Reveles, K. R., Attridge, R. T., Lawson, K. A., Mansi, I. A., Lewis, J. S., & Frei, C. R. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-96 · Cited by 231
Donà, D., Barbieri, E., Daverio, M., Lundin, R., Giaquinto, C., Zaoutis, T., & Sharland, M. (2020) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-019-0659-3 · Cited by 199
Tran, T. T., Panesso, D., Mishra, N. N., Mileykovskaya, E., Guan, Z., Munita, J. M., Reyes, J., Diaz, L., Weinstock, G. M., Murray, B. E., et al. (2013) · mBio · doi:10.1128/mbio.00281-13 · Cited by 192
Chen, M. X., Alexander, K. S., & Baki, G. (2016) · Journal of Pharmaceutics · doi:10.1155/2016/5754349 · Cited by 173
Systems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159
Klebba, P. E., Newton, S. M. C., Six, D. A., Kumar, A., Yang, T., Nairn, B. L., Munger, C., & Chakravorty, S. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01005 · Cited by 150
Sartelli, M., C. Hardcastle, T., Catena, F., Chichom-Mefire, A., Coccolini, F., Dhingra, S., Haque, M., Hodonou, A., Iskandar, K., Labricciosa, F. M., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9080497 · Cited by 149
Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens
Hijazi, S., Visaggio, D., Pirolo, M., Frangipani, E., Bernstein, L., & Visca, P. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00316 · Cited by 144
“ESKAPE pathogens rank among the most prevalent causative agents of healthcare-associated infections, and pose a serious therapeutic challenge due to their resistance to available antibiotics (Boucher et al., 2009).”
Background(2015) · doi:10.1016/j.jinf.2014.10.004 · Cited by 143
Aslam, A., Gajdács, M., Zin, C. S., Ab Rahman, N. S., Ahmed, S. I., Zafar, M. Z., & Jamshed, S. (2020) · Antibiotics · doi:10.3390/antibiotics9090597 · Cited by 142
Antibacterial Activities of Iron Chelators against Common Nosocomial Pathogens
Thompson, M. G., Corey, B. W., Si, Y., Craft, D. W., & Zurawski, D. V. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01197-12 · Cited by 135
Okumura, C. Y. M., Hollands, A., Tran, D. N., Olson, J., Dahesh, S., von Köckritz-Blickwede, M., Thienphrapa, W., Corle, C., Jeung, S. N., Kotsakis, A., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0882-3 · Cited by 115
Munita, J. M., Panesso, D., Diaz, L., Tran, T. T., Reyes, J., Wanger, A., Murray, B. E., & Arias, C. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00509-12 · Cited by 118
Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy
Casapao, A. M., Davis, S. L., Barr, V. O., Klinker, K. P., Goff, D. A., Barber, K. E., Kaye, K. S., Mynatt, R. P., Molloy, L. M., Pogue, J. M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02371-13 · Cited by 108
Kim, B., Park, J.-S., Choi, H.-Y., Yoon, S. S., & Kim, W.-G. (2018) · Scientific Reports · doi:10.1038/s41598-018-26974-5 · Cited by 103
Alkofide, H., Alhammad, A. M., Alruwaili, A., Aldemerdash, A., Almangour, T. A., Alsuwayegh, A., Almoqbel, D., Albati, A., Alsaud, A., & Enani, M. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s283488 · Cited by 96
Charusanti, P., Fong, N. L., Nagarajan, H., Pereira, A. R., Li, H. J., Abate, E. A., Su, Y., Gerwick, W. H., & Palsson, B. O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033727 · Cited by 93
(2014) · doi:10.1097/mcc.0000000000000124 · Cited by 89
Yokota, P. K. O., Marra, A. R., Martino, M. D. V., Victor, E. S., Durão, M. S., Edmond, M. B., & dos Santos, O. F. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104475 · Cited by 85
“Of the ESKAPE pathogens [19,20], which have paramount importance due to the their pathogenesis, transmission mode and antimicrobial resistance, the most common was E.”
Background
Metadata
- Authors
- Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01
- Volume
- 48
- Issue
- 1
- Pages
- 1-12
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2115486016
- Cited by
- 4,958
- References
- 66
- FWCI
- 162.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.